BioPorto (NASDAQ COPENHAG:BIOPOR) A/S has announced the appointment of pediatric nephrology specialist Dr Prasad Devarajan as senior medical director effective July 1, 2022.
Dr Devarajan is considered a world-leading pediatric nephrologist and physician-scientist and a pioneer in understanding the relationship between Neutrophil gelatinase-associated lipocalin (NGAL) and Acute Kidney Injury (AKI), the company said.
“Dr Devarajan’s unparalleled reputation, knowledge, and expertise will be a tremendous gain for BioPorto (NASDAQ COPENHAG:BIOPOR) as we expand the global market’s understanding of the benefits of The NGAL Test and prepare its submission for FDA review and approval,” said BioPorto (NASDAQ COPENHAG:BIOPOR) CEO Tony Pare in a statement.
READ: BioPorto says 1Q revenue rises by 17%, boosted by strong sales growth for its NGAL test
BioPorto (NASDAQ COPENHAG:BIOPOR) said Dr Devarajan is Professor of Pediatrics and Developmental Biology, director of Nephrology and Hypertension, and CEO of the Dialysis Unit at Cincinnati Children’s Hospital Medical Center in Ohio, US.
He is also one of the most frequently cited authors of peer-reviewed literature on the topics of kidney disease, nephrology, and renal disease, the company said, adding that Dr Devarajan will share his time between his directorships at Cincinnati Children’s Hospital and his executive role at BioPorto.
“I have been working with BioPorto for many years and am truly impressed with The NGAL Test and its unique potential to save lives. I believe that access to The NGAL Test as a kidney injury assessment tool will be a major milestone for kidney disease patients and physicians. I am confident The NGAL Test will redefine the diagnosis of AKI going forward,” Dr Devarajan said.
“From a physician’s and scientist’s point-of-view, it will be a privilege to help expand applications and indications for NGAL assays while also evaluating new areas of growth for BioPorto in the field of kidney health. I also look forward to further educating the medical and scientific community on The NGAL Test and ultimately assisting in developing and bringing tests to the market that improve patient outcomes,” he added.
In addition to his appointments at Cincinnati Children’s Hospital, Dr Devarajan serves on the editorial and review boards of more than 20 journals and on multiple US National Institutes of Health (NIH) study sections, and has authored more than 320 peer-reviewed journal articles, BioPorto said, noting that his work has been continuously funded by NIH and several other foundations for more than thirty years.
“I am extremely excited and proud to have a world-renowned nephrologist and NGAL expert join BioPorto as senior medical director,” said BioPorto CEO Pare.
BioPorto is an in-vitro diagnostics company that provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies. Its pioneering product portfolio includes assays for underserved disease states such as NGAL for acute kidney injury. The company sells its products in more than 80 countries through diverse sales channels and partners. BioPorto has its headquarters in Copenhagen, Denmark and is listed on the Nasdaq Copenhagen stock exchange.
Contact the author at jon.hopkins@proactiveinvestors.com